Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock
NASDAQ · ZNTL
3.03
Fundamentals
Market cap
$294.43M
Price / Earnings ratio
-1.6x
Price / Sales ratio
-4.8x
Price / Book ratio
1.6x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Zentalis Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees106
CEOMs. Julie M. Eastland M.B.A.
IPO DateApr 3, 2020
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Julie M. Eastland M.B.A. | CEO, President & Director | 1964 |
| Mr. James B. Bucher J.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer | 1975 |
| Mr. Vincent A. Vultaggio | SVP of Finance & Principal Accounting Officer | 1984 |
| Mr. Robert J. DiVasto P.E. | Chief Technical Officer | 1956 |
| Ms. Wendy Chang | Chief People Officer | — |
| Mr. Haibo Wang | Chief Business Officer | — |
| Mr. Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing | — |
| Mr. Henry Gu | Senior VP & Head of Intellectual Property | — |
| Ms. Sarah Kelly | Senior Vice President of Commercial Strategy | — |
Fundamentals
Valuation
Market cap$294.43M
Price-to-sales ratio-4.76
Price-to-book value1.55
Price-earnings ratio-1.60
Return on Equity-54.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.95
Income Statement
Average volume875,551
EBITDA$-122.94M
1 year high (52w)$6.95
1 year low (52w)$1.21
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



